Search by Drug Name or NDC
NDC 00409-2337-25 Deferoxamine Mesylate 2 g/1 Details
Deferoxamine Mesylate 2 g/1
Deferoxamine Mesylate is a INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Hospira, Inc.. The primary component is DEFEROXAMINE MESYLATE.
Product Information
| NDC | 00409-2337 |
|---|---|
| Product ID | 0409-2337_a1126531-9102-4c43-9192-87d6943e19f0 |
| Associated GPIs | 93000020102130 |
| GCN Sequence Number | 015181 |
| GCN Sequence Number Description | deferoxamine mesylate VIAL 2 G INJECTION |
| HIC3 | C8A |
| HIC3 Description | METALLIC POISON,AGENTS TO TREAT |
| GCN | 07112 |
| HICL Sequence Number | 001104 |
| HICL Sequence Number Description | DEFEROXAMINE MESYLATE |
| Brand/Generic | Generic |
| Proprietary Name | Deferoxamine Mesylate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Deferoxamine Mesylate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRAMUSCULAR; INTRAVENOUS; SUBCUTANEOUS |
| Active Ingredient Strength | 2 |
| Active Ingredient Units | g/1 |
| Substance Name | DEFEROXAMINE MESYLATE |
| Labeler Name | Hospira, Inc. |
| Pharmaceutical Class | Iron Chelating Activity [MoA], Iron Chelator [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA076019 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00409-2337-25 (00409233725)
| NDC Package Code | 0409-2337-25 |
|---|---|
| Billing NDC | 00409233725 |
| Package | 4 VIAL, SINGLE-USE in 1 CARTON (0409-2337-25) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE (0409-2337-15) |
| Marketing Start Date | 2005-03-31 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |